Stephanie Holland

Conference Coverage

New Patient Visits via Telehealth Improve Management of Patients With Monoclonal Gammopathy of Undetermined Significance at Increased Risk for Hematological Cancers

11/14/2024

Stephanie Holland ;

Conducting new patient visits via telehealth with advanced practice providers allows for quicker identification, assessment, and surveillance of patients with monoclonal gammopathy of undetermined significance at increased risk of developing...

Conducting new patient visits...

11/14/2024

APP Institute Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Addition of Ovarian Suppression to Adjuvant Tamoxifen Significantly Improved DFS Among Premenopausal Patients With ER-Positive Breast Cancer

12/14/2023

Stephanie Holland ;

According to post-trial follow-up results from the ASTRRA trial, adjuvant tamoxifen plus ovarian function suppression significantly improved DFS rate with no negative impact on OS among premenopausal patients with pretreated estrogen...

According to post-trial...

12/14/2023

Oncology

Conference Coverage

Fianlimab Plus Cemiplimab Exhibits High Clinical Activity and Tolerable Safety in Advanced Melanoma

06/19/2023

Stephanie Holland ;

Data from a phase 1 trial show that combined treatment with fianlimab plus cemiplimab exhibits high clinical activity and tolerable safety in advanced melanoma, consistent with other approved combinations of immune checkpoint inhibitors in...

Data from a phase 1 trial show...

06/19/2023

Oncology

FDA Approval

FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations

01/20/2024

Stephanie Holland ;

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

Based on results from cohort 1...

01/20/2024

Oncology